Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Hepatitis CThalassemia
Interventions
DRUG

PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)

PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: \[=\<75 kg: 1000 mg; \>75 kg: 1200 mg per day (PO)\]

Trial Locations (1)

14155-3651

Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Tehran

All Listed Sponsors
collaborator

Baqiyatallah Research Center for Gastroenterology and Liver Diseases

OTHER

collaborator

Tehran Hepatitis Center

OTHER

collaborator

Guilan University of Medical Sciences

OTHER

collaborator

Tabriz Research Center for Gastroenterology and Liver Diseases

UNKNOWN

lead

Baqiyatallah Medical Sciences University

OTHER

NCT00707850 - Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection | Biotech Hunter | Biotech Hunter